Pradaxa®

DRUG2 trials

Sponsors

Boehringer Ingelheim, Hong Kong WD Pharmaceutical Co., Limited

Conditions

AnticoagulantAtrial Fibrillation

Phase 1

A Single Dose Bioequivalence Study of WD-1602 Versus Pradaxa® in Healthy Subjects Under Fed Condition

Hong Kong WD Pharmaceutical Co., LimitedAnticoagulant

Start: 2021-01-06End: 2021-12-06Target: 20Updated: 2020-11-02

Unknown Phase

Patients' Assessment of Satisfaction for Stroke Prevention in Atrial Fibrillation

CompletedNCT03187197

Boehringer IngelheimAtrial Fibrillation

Start: 2017-06-20End: 2019-01-11Updated: 2020-02-24